Multi Specialty Research Associates Inc — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2023	Research	$10,142	3
2022	Research	$59,258	19
2021	Research	$25,210	11

Breakdown

Who paid Research payments · program years 2021–2023

Biohaven Pharmaceutical Holding Company Ltd. $61,138 20 payments
Biohaven Pharmaceuticals, Inc. $25,210 11 payments
Lexicon Pharmaceuticals, Inc. $8,262 2 payments

Studies the money was for Research payments · program years 2021–2023

A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $43,191 11 payments
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age $20,476 9 payments
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age $13,708 8 payments
Relief-Dpn 1 $8,262 2 payments
Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age $3,671 1 payment
Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents ? 6 to <18 Years of Age $3,422 1 payment
A Phase 23 Randomized Doubleblind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $1,880 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.